No black box warning on record for Reyataz

As of the latest FDA labeling reviewed, Reyataz (ATAZANAVIR) does not carry a black box warning. Standard warnings and precautions still apply — see the full Reyataz medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS • Cardiac conduction abnormalities: PR interval prolongation may occur in some patients. ECG monitoring should be considered in patients with preexisting conduction system disease or when administered with other drugs that may prolong the PR interval. (5.1 , 7.3 , 12.2 , 17) • Severe Skin Reactions: Discontinue if severe rash develops. (5.2 , 17) • Hyperbilirubinemia: Mo

No black box warning on record for Reyataz

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS • Cardiac conduction abnormalities: PR interval prolongation may occur in some patients. ECG monitoring should be considered in patients with preexisting conduction system disease or when administered with other drugs that may prolong the PR interval. (5.1 , 7.3 , 12.2 , 17) • Severe Skin Reactions: Discontinue if severe rash develops. (5.2 , 17) • Hyperbilirubinemia: Mo

Reyataz Black Box Warning

No black box warning on record for Reyataz

Other warnings & precautions

Reyataz Black Box Warning

No black box warning on record for Reyataz

Other warnings & precautions